BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 25159327)

  • 1. Leptin restores the insulinotropic effect of exenatide in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and high-fat diet.
    Sakai T; Kusakabe T; Ebihara K; Aotani D; Yamamoto-Kataoka S; Zhao M; Gumbilai VM; Ebihara C; Aizawa-Abe M; Yamamoto Y; Noguchi M; Fujikura J; Hosoda K; Inagaki N; Nakao K
    Am J Physiol Endocrinol Metab; 2014 Oct; 307(8):E712-9. PubMed ID: 25159327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amylin improves the effect of leptin on insulin sensitivity in leptin-resistant diet-induced obese mice.
    Kusakabe T; Ebihara K; Sakai T; Miyamoto L; Aotani D; Yamamoto Y; Yamamoto-Kataoka S; Aizawa-Abe M; Fujikura J; Hosoda K; Nakao K
    Am J Physiol Endocrinol Metab; 2012 Apr; 302(8):E924-31. PubMed ID: 22275759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice.
    Irwin N; Hunter K; Montgomery IA; Flatt PR
    Diabetes Obes Metab; 2013 Jul; 15(7):650-9. PubMed ID: 23388064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of exenatide on metabolic parameters/control in obese Japanese patients with type 2 diabetes.
    Tokuda M; Katsuno T; Ochi F; Miyakoshi K; Kusunoki Y; Murai K; Miuchi M; Hamaguchi T; Miyagawa J; Namba M
    Endocr J; 2014; 61(4):365-72. PubMed ID: 24452017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gender-related different effects of a combined therapy of Exenatide and Metformin on overweight or obesity patients with type 2 diabetes mellitus.
    Quan H; Zhang H; Wei W; Fang T
    J Diabetes Complications; 2016; 30(4):686-92. PubMed ID: 26873871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exenatide reverses dysregulated microRNAs in high-fat diet-induced obese mice.
    Lee IS; Park KC; Yang KJ; Choi H; Jang YS; Lee JM; Kim HS
    Obes Res Clin Pract; 2016; 10(3):315-26. PubMed ID: 26314504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice.
    Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
    Peptides; 2018 Feb; 100():202-211. PubMed ID: 29412820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-like peptide-1 and islet lipolysis.
    Sörhede Winzell M; Ahrén B
    Horm Metab Res; 2004; 36(11-12):795-803. PubMed ID: 15655711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents.
    Trevaskis JL; Sun C; Athanacio J; D'Souza L; Samant M; Tatarkiewicz K; Griffin PS; Wittmer C; Wang Y; Teng CH; Forood B; Parkes DG; Roth JD
    Diabetes Obes Metab; 2015 Jan; 17(1):61-73. PubMed ID: 25204356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to fight obesity with antidiabetic drugs: targeting gut or kidney?
    Baretić M; Troskot R
    Minerva Endocrinol; 2015 Mar; 40(1):71-83. PubMed ID: 25366984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial long-term antidiabetic actions of N- and C-terminally modified analogues of apelin-13 in diet-induced obese diabetic mice.
    Parthsarathy V; Hogg C; Flatt PR; O'Harte FPM
    Diabetes Obes Metab; 2018 Feb; 20(2):319-327. PubMed ID: 28730728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy.
    Dutour A; Abdesselam I; Ancel P; Kober F; Mrad G; Darmon P; Ronsin O; Pradel V; Lesavre N; Martin JC; Jacquier A; Lefur Y; Bernard M; Gaborit B
    Diabetes Obes Metab; 2016 Sep; 18(9):882-91. PubMed ID: 27106272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial effects of leptin on glycaemic and lipid control in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and a high-fat diet.
    Kusakabe T; Tanioka H; Ebihara K; Hirata M; Miyamoto L; Miyanaga F; Hige H; Aotani D; Fujisawa T; Masuzaki H; Hosoda K; Nakao K
    Diabetologia; 2009 Apr; 52(4):675-83. PubMed ID: 19169663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes.
    Tanday N; English A; Lafferty RA; Flatt PR; Irwin N
    Front Endocrinol (Lausanne); 2021; 12():674704. PubMed ID: 34054734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, augments the effects of orally delivered exenatide and pramlintide acetate on energy balance and glycemic control in insulin-resistant male C57BLK/6-m db/db mice.
    Leinung MC; Grasso P
    Regul Pept; 2012 Nov; 179(1-3):33-8. PubMed ID: 22960403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of the beneficial and protective effects of exenatide in diabetic rats.
    Lotfy M; Singh J; Rashed H; Tariq S; Zilahi E; Adeghate E
    J Endocrinol; 2014 Mar; 220(3):291-304. PubMed ID: 24353307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
    Patel KN; Joharapurkar AA; Patel V; Kshirsagar SG; Bahekar R; Srivastava BK; Jain MR
    Can J Physiol Pharmacol; 2014 Dec; 92(12):975-83. PubMed ID: 25361428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exenatide and weight loss.
    Bradley DP; Kulstad R; Schoeller DA
    Nutrition; 2010 Mar; 26(3):243-9. PubMed ID: 20152707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures.
    Mack CM; Moore CX; Jodka CM; Bhavsar S; Wilson JK; Hoyt JA; Roan JL; Vu C; Laugero KD; Parkes DG; Young AA
    Int J Obes (Lond); 2006 Sep; 30(9):1332-40. PubMed ID: 16534527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.